Viral miRNAs as Active Players and Participants in Tumorigenesis
Abstract
:1. Introduction
2. Epstein–Barr Virus (EBV)
3. Kaposi’s Sarcoma Herpesvirus/Human Herpesvirus-8 (KSHV/HHV8)
4. Human Papillomavirus (HPV)
5. Hepatitis B Virus (HBV)
6. Hepatitis C Virus (HCV)
7. Merkel Cell Polyomavirus (MCPyV)
8. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- De Martel, C.; Georges, D.; Bray, F.; Ferlay, J.; Clifford, G.M. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. Lancet Glob. Health 2019. [Google Scholar] [CrossRef] [Green Version]
- Moore, P.S.; Chang, Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat. Rev. Cancer 2010, 10, 878–889. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Grulich, A.E.; van Leeuwen, M.T.; Falster, M.O.; Vajdic, C.M. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 2007, 370, 59–67. [Google Scholar] [CrossRef]
- Chin, Y.E.; Kitagawa, M.; Su, W.C.; You, Z.H.; Iwamoto, Y.; Fu, X.Y. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 1996, 272, 719–722. [Google Scholar] [CrossRef] [PubMed]
- Takaoka, A.; Hayakawa, S.; Yanai, H.; Stoiber, D.; Negishi, H.; Kikuchi, H.; Sasaki, S.; Imai, K.; Shibue, T.; Honda, K.; et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003, 424, 516–523. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Moore, P.S.; Chang, Y. Kaposi’s sarcoma-associated herpesvirus immunoevasion and tumorigenesis: Two sides of the same coin? Annu. Rev. Microbiol. 2003, 57, 609–639. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Moore, P.S.; Chang, Y. Antiviral activity of tumor-suppressor pathways: Clues from molecular piracy by KSHV. Trends Genet. 1998, 14, 144–150. [Google Scholar] [CrossRef]
- Vojtechova, Z.; Tachezy, R. The Role of miRNAs in Virus-Mediated Oncogenesis. Int. J. Mol. Sci. 2018, 19, 1217. [Google Scholar] [CrossRef] [Green Version]
- Skalsky, R.L.; Cullen, B.R. Viruses, microRNAs, and host interactions. Annu. Rev. Microbiol. 2010, 64, 123–141. [Google Scholar] [CrossRef] [Green Version]
- Gottwein, E.; Mukherjee, N.; Sachse, C.; Frenzel, C.; Majoros, W.H.; Chi, J.T.; Braich, R.; Manoharan, M.; Soutschek, J.; Ohler, U.; et al. A viral microRNA functions as an orthologue of cellular miR-155. Nature 2007, 450, 1096–1099. [Google Scholar] [CrossRef]
- Gottwein, E.; Corcoran, D.L.; Mukherjee, N.; Skalsky, R.L.; Hafner, M.; Nusbaum, J.D.; Shamulailatpam, P.; Love, C.L.; Dave, S.S.; Tuschl, T.; et al. Viral microRNA targetome of KSHV-infected primary effusion lymphoma cell lines. Cell Host Microbe 2011, 10, 515–526. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Manzano, M.; Shamulailatpam, P.; Raja, A.N.; Gottwein, E. Kaposi’s sarcoma-associated herpesvirus encodes a mimic of cellular miR-23. J. Virol. 2013, 87, 11821–11830. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Babu, S.G.; Ponia, S.S.; Kumar, D.; Saxena, S. Cellular oncomiR orthologue in EBV oncogenesis. Comput. Biol. Med. 2011, 41, 891–898. [Google Scholar] [CrossRef]
- Naqvi, A.R. Immunomodulatory roles of human herpesvirus-encoded microRNA in host-virus interaction. Rev. Med. Virol. 2020, 30, e2081. [Google Scholar] [CrossRef]
- Weng, S.L.; Huang, K.Y.; Weng, J.T.; Hung, F.Y.; Chang, T.H.; Lee, T.Y. Genome-wide discovery of viral microRNAs based on phylogenetic analysis and structural evolution of various human papillomavirus subtypes. Brief. Bioinform. 2018, 19, 1102–1114. [Google Scholar] [CrossRef] [PubMed]
- Kutok, J.L.; Wang, F. Spectrum of Epstein-Barr virus-associated diseases. Annu. Rev. Pathol. 2006, 1, 375–404. [Google Scholar] [CrossRef] [PubMed]
- Fries, K.L.; Miller, W.E.; Raab-Traub, N. Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. J. Virol. 1996, 70, 8653–8659. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Raab-Traub, N. EBV-induced oncogenesis. In Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis; Arvin, A., Campadelli-Fiume, G., Mocarski, E., Moore, P.S., Roizman, B., Whitley, R., Yamanishi, K., Eds.; Cambridge University Press: Cambridge, UK, 2007; Chapter 55. [Google Scholar]
- Murata, T. Regulation of Epstein-Barr virus reactivation from latency. Microbiol. Immunol. 2014, 58, 307–317. [Google Scholar] [CrossRef] [PubMed]
- Sinclair, A.J. Epigenetic control of Epstein-Barr virus transcription—Relevance to viral life cycle? Front. Genet. 2013, 4, 161. [Google Scholar] [CrossRef] [Green Version]
- Andrei, G.; Trompet, E.; Snoeck, R. Novel Therapeutics for Epstein(-)Barr Virus. Molecules 2019, 24, 997. [Google Scholar] [CrossRef] [Green Version]
- Cesarman, E.; Mesri, E.A. Kaposi sarcoma-associated herpesvirus and other viruses in human lymphomagenesis. Curr. Top. Microbiol. Immunol. 2007, 312, 263–287. [Google Scholar] [PubMed]
- Pfeffer, S.; Zavolan, M.; Grasser, F.A.; Chien, M.; Russo, J.J.; Ju, J.; John, B.; Enright, A.J.; Marks, D.; Sander, C.; et al. Identification of virus-encoded microRNAs. Science 2004, 304, 734–736. [Google Scholar] [CrossRef] [PubMed]
- Barth, S.; Meister, G.; Grasser, F.A. EBV-encoded miRNAs. Biochim. Biophys. Acta 2011, 1809, 631–640. [Google Scholar] [CrossRef] [PubMed]
- Klinke, O.; Feederle, R.; Delecluse, H.J. Genetics of Epstein-Barr virus microRNAs. Semin. Cancer Biol. 2014, 26, 52–59. [Google Scholar] [CrossRef]
- Kang, M.S.; Kieff, E. Epstein-Barr virus latent genes. Exp. Mol. Med. 2015, 47, e131. [Google Scholar] [CrossRef] [Green Version]
- Amoroso, R.; Fitzsimmons, L.; Thomas, W.A.; Kelly, G.L.; Rowe, M.; Bell, A.I. Quantitative studies of Epstein-Barr virus-encoded microRNAs provide novel insights into their regulation. J. Virol. 2011, 85, 996–1010. [Google Scholar] [CrossRef] [Green Version]
- Zhang, X.; Ye, Y.; Fu, M.; Zheng, B.; Qiu, Q.; Huang, Z. Implication of viral microRNAs in the genesis and diagnosis of Epstein-Barr virus-associated tumors. Oncol. Lett. 2019, 18, 3433–3442. [Google Scholar] [CrossRef]
- Ye, Y.; Zhou, Y.; Zhang, L.; Chen, Y.; Lyu, X.; Cai, L.; Lu, Y.; Deng, Y.; Wang, J.; Yao, K.; et al. EBV-miR-BART1 is involved in regulating metabolism-associated genes in nasopharyngeal carcinoma. Biochem. Biophys. Res. Commun. 2013, 436, 19–24. [Google Scholar] [CrossRef]
- Choy, E.Y.; Siu, K.L.; Kok, K.H.; Lung, R.W.; Tsang, C.M.; To, K.F.; Kwong, D.L.; Tsao, S.W.; Jin, D.Y. An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. J. Exp. Med. 2008, 205, 2551–2560. [Google Scholar] [CrossRef] [Green Version]
- Zheng, X.; Wang, J.; Wei, L.; Peng, Q.; Gao, Y.; Fu, Y.; Lu, Y.; Qin, Z.; Zhang, X.; Lu, J.; et al. Epstein-Barr Virus MicroRNA miR-BART5-3p Inhibits p53 Expression. J. Virol. 2018, 92, e01022-18. [Google Scholar] [CrossRef] [Green Version]
- Cai, L.; Ye, Y.; Jiang, Q.; Chen, Y.; Lyu, X.; Li, J.; Wang, S.; Liu, T.; Cai, H.; Yao, K.; et al. Epstein-Barr virus-encoded microRNA BART1 induces tumour metastasis by regulating PTEN-dependent pathways in nasopharyngeal carcinoma. Nat. Commun. 2015, 6, 7353. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cai, L.M.; Lyu, X.M.; Luo, W.R.; Cui, X.F.; Ye, Y.F.; Yuan, C.C.; Peng, Q.X.; Wu, D.H.; Liu, T.F.; Wang, E.; et al. EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN. Oncogene 2015, 34, 2156–2166. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ambrosio, M.R.; Navari, M.; Di Lisio, L.; Leon, E.A.; Onnis, A.; Gazaneo, S.; Mundo, L.; Ulivieri, C.; Gomez, G.; Lazzi, S.; et al. The Epstein Barr-encoded BART-6-3p microRNA affects regulation of cell growth and immuno response in Burkitt lymphoma. Infect. Agents Cancer 2014, 9, 12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kanda, T.; Miyata, M.; Kano, M.; Kondo, S.; Yoshizaki, T.; Iizasa, H. Clustered microRNAs of the Epstein-Barr virus cooperatively downregulate an epithelial cell-specific metastasis suppressor. J. Virol. 2015, 89, 2684–2697. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shinozaki-Ushiku, A.; Kunita, A.; Isogai, M.; Hibiya, T.; Ushiku, T.; Takada, K.; Fukayama, M. Profiling of Virus-Encoded MicroRNAs in Epstein-Barr Virus-Associated Gastric Carcinoma and Their Roles in Gastric Carcinogenesis. J. Virol. 2015, 89, 5581–5591. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, R.; Zhang, M.; Li, Q.; Xiong, H.; Liu, S.; Fang, W.; Zhang, Q.; Liu, Z.; Xu, X.; Jiang, Q. The Epstein-Barr Virus-encoded miR-BART22 targets MAP3K5 to promote host cell proliferative and invasive abilities in nasopharyngeal carcinoma. J. Cancer 2017, 8, 305–313. [Google Scholar] [CrossRef] [Green Version]
- Kim, H.; Choi, H.; Lee, S.K. Epstein-Barr virus miR-BART20-5p regulates cell proliferation and apoptosis by targeting BAD. Cancer Lett. 2015, 356, 733–742. [Google Scholar] [CrossRef]
- Song, Y.; Li, X.; Zeng, Z.; Li, Q.; Gong, Z.; Liao, Q.; Li, X.; Chen, P.; Xiang, B.; Zhang, W.; et al. Epstein-Barr virus encoded miR-BART11 promotes inflammation-induced carcinogenesis by targeting FOXP1. Oncotarget 2016, 7, 36783–36799. [Google Scholar] [CrossRef] [Green Version]
- Hsu, C.Y.; Yi, Y.H.; Chang, K.P.; Chang, Y.S.; Chen, S.J.; Chen, H.C. The Epstein-Barr virus-encoded microRNA MiR-BART9 promotes tumor metastasis by targeting E-cadherin in nasopharyngeal carcinoma. Plos Pathog. 2014, 10, e1003974. [Google Scholar] [CrossRef]
- Yan, Q.; Zeng, Z.; Gong, Z.; Zhang, W.; Li, X.; He, B.; Song, Y.; Li, Q.; Zeng, Y.; Liao, Q.; et al. EBV-miR-BART10-3p facilitates epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma by targeting BTRC. Oncotarget 2015, 6, 41766–41782. [Google Scholar] [CrossRef] [Green Version]
- Pegtel, D.M.; Cosmopoulos, K.; Thorley-Lawson, D.A.; van Eijndhoven, M.A.; Hopmans, E.S.; Lindenberg, J.L.; de Gruijl, T.D.; Wurdinger, T.; Middeldorp, J.M. Functional delivery of viral miRNAs via exosomes. Proc. Natl. Acad. Sci. USA 2010, 107, 6328–6333. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gallo, A.; Jang, S.I.; Ong, H.L.; Perez, P.; Tandon, M.; Ambudkar, I.; Illei, G.; Alevizos, I. Targeting the Ca(2+) Sensor STIM1 by Exosomal Transfer of Ebv-miR-BART13-3p is Associated with Sjogren’s Syndrome. EBioMedicine 2016, 10, 216–226. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gallo, A.; Vella, S.; Miele, M.; Timoneri, F.; Di Bella, M.; Bosi, S.; Sciveres, M.; Conaldi, P.G. Global profiling of viral and cellular non-coding RNAs in Epstein-Barr virus-induced lymphoblastoid cell lines and released exosome cargos. Cancer Lett. 2017, 388, 334–343. [Google Scholar] [CrossRef] [PubMed]
- Li, Z.; Chen, X.; Li, L.; Liu, S.; Yang, L.; Ma, X.; Tang, M.; Bode, A.M.; Dong, Z.; Sun, L.; et al. EBV encoded miR-BHRF1-1 potentiates viral lytic replication by downregulating host p53 in nasopharyngeal carcinoma. Int. J. Biochem. Cell Biol. 2012, 44, 275–279. [Google Scholar] [CrossRef] [PubMed]
- Lu, Y.; Qin, Z.; Wang, J.; Zheng, X.; Lu, J.; Zhang, X.; Wei, L.; Peng, Q.; Zheng, Y.; Ou, C.; et al. Epstein-Barr Virus miR-BART6-3p Inhibits the RIG-I Pathway. J. Innate Immun. 2017, 9, 574–586. [Google Scholar] [CrossRef]
- Zhang, Y.M.; Yu, Y.; Zhao, H.P. EBVBART63p and cellular microRNA197 compromise the immune defense of host cells in EBVpositive Burkitt lymphoma. Mol. Med. Rep. 2017, 15, 1877–1883. [Google Scholar] [CrossRef]
- Hooykaas, M.J.G.; van Gent, M.; Soppe, J.A.; Kruse, E.; Boer, I.G.J.; van Leenen, D.; Groot Koerkamp, M.J.A.; Holstege, F.C.P.; Ressing, M.E.; Wiertz, E.; et al. EBV MicroRNA BART16 Suppresses Type I IFN Signaling. J. Immunol. 2017, 198, 4062–4073. [Google Scholar] [CrossRef] [Green Version]
- Skinner, C.M.; Ivanov, N.S.; Barr, S.A.; Chen, Y.; Skalsky, R.L. An Epstein-Barr Virus MicroRNA Blocks Interleukin-1 (IL-1) Signaling by Targeting IL-1 Receptor 1. J. Virol. 2017, 91, e00530-17. [Google Scholar] [CrossRef] [Green Version]
- Haneklaus, M.; Gerlic, M.; Kurowska-Stolarska, M.; Rainey, A.A.; Pich, D.; McInnes, I.B.; Hammerschmidt, W.; O’Neill, L.A.; Masters, S.L. Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1beta production. J. Immunol. 2012, 189, 3795–3799. [Google Scholar] [CrossRef] [Green Version]
- Tagawa, T.; Albanese, M.; Bouvet, M.; Moosmann, A.; Mautner, J.; Heissmeyer, V.; Zielinski, C.; Lutter, D.; Hoser, J.; Hastreiter, M.; et al. Epstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing. J. Exp. Med. 2016, 213, 2065–2080. [Google Scholar] [CrossRef] [PubMed]
- Skalsky, R.L.; Corcoran, D.L.; Gottwein, E.; Frank, C.L.; Kang, D.; Hafner, M.; Nusbaum, J.D.; Feederle, R.; Delecluse, H.J.; Luftig, M.A.; et al. The viral and cellular microRNA targetome in lymphoblastoid cell lines. PLoS Pathog. 2012, 8, e1002484. [Google Scholar] [CrossRef] [PubMed]
- Xia, T.; O’Hara, A.; Araujo, I.; Barreto, J.; Carvalho, E.; Sapucaia, J.B.; Ramos, J.C.; Luz, E.; Pedroso, C.; Manrique, M.; et al. EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res. 2008, 68, 1436–1442. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ganem, D. Human herpesvirus 8 and its role in the genesis of Kaposi’s sarcoma. Curr. Clin. Top. Infect. Dis. 1998, 18, 237–251. [Google Scholar] [PubMed]
- Rappocciolo, G.; Jenkins, F.J.; Hensler, H.R.; Piazza, P.; Jais, M.; Borowski, L.; Watkins, S.C.; Rinaldo, C.R., Jr. DC-SIGN is a receptor for human herpesvirus 8 on dendritic cells and macrophages. J. Immunol. 2006, 176, 1741–1749. [Google Scholar] [CrossRef]
- Ganem, D. KSHV and the pathogenesis of Kaposi sarcoma: Listening to human biology and medicine. J. Clin. Investig. 2010, 120, 939–949. [Google Scholar] [CrossRef]
- Chang, Y.; Cesarman, E.; Pessin, M.S.; Lee, F.; Culpepper, J.; Knowles, D.M.; Moore, P.S. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994, 266, 1865–1869. [Google Scholar] [CrossRef] [Green Version]
- Nador, R.G.; Cesarman, E.; Chadburn, A.; Dawson, D.B.; Ansari, M.Q.; Sald, J.; Knowles, D.M. Primary effusion lymphoma: A distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood 1996, 88, 645–656. [Google Scholar] [CrossRef] [Green Version]
- Soulier, J.; Grollet, L.; Oksenhendler, E.; Cacoub, P.; Cazals-Hatem, D.; Babinet, P.; d’Agay, M.F.; Clauvel, J.P.; Raphael, M.; Degos, L.; et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 1995, 86, 1276–1280. [Google Scholar] [CrossRef] [Green Version]
- Arias, C.; Weisburd, B.; Stern-Ginossar, N.; Mercier, A.; Madrid, A.S.; Bellare, P.; Holdorf, M.; Weissman, J.S.; Ganem, D. KSHV 2.0: A comprehensive annotation of the Kaposi’s sarcoma-associated herpesvirus genome using next-generation sequencing reveals novel genomic and functional features. PLoS Pathog. 2014, 10, e1003847. [Google Scholar] [CrossRef]
- Lin, Y.T.; Kincaid, R.P.; Arasappan, D.; Dowd, S.E.; Hunicke-Smith, S.P.; Sullivan, C.S. Small RNA profiling reveals antisense transcription throughout the KSHV genome and novel small RNAs. RNA 2010, 16, 1540–1558. [Google Scholar] [CrossRef] [Green Version]
- Cai, X.; Lu, S.; Zhang, Z.; Gonzalez, C.M.; Damania, B.; Cullen, B.R. Kaposi’s sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc. Natl. Acad. Sci. USA 2005, 102, 5570–5575. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Piedade, D.; Azevedo-Pereira, J.M. The Role of microRNAs in the Pathogenesis of Herpesvirus Infection. Viruses 2016, 8, 156. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Suffert, G.; Malterer, G.; Hausser, J.; Viiliainen, J.; Fender, A.; Contrant, M.; Ivacevic, T.; Benes, V.; Gros, F.; Voinnet, O.; et al. Kaposi’s sarcoma herpesvirus microRNAs target caspase 3 and regulate apoptosis. PLoS Pathog. 2011, 7, e1002405. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, M.; Sun, F.; Han, L.; Qu, Z. Kaposi’s sarcoma herpesvirus (KSHV) microRNA K12-1 functions as an oncogene by activating NF-kappaB/IL-6/STAT3 signaling. Oncotarget 2016, 7, 33363–33373. [Google Scholar] [PubMed]
- Hu, M.; Wang, C.; Li, W.; Lu, W.; Bai, Z.; Qin, D.; Yan, Q.; Zhu, J.; Krueger, B.J.; Renne, R.; et al. A KSHV microRNA Directly Targets G Protein-Coupled Receptor Kinase 2 to Promote the Migration and Invasion of Endothelial Cells by Inducing CXCR2 and Activating AKT Signaling. PLoS Pathog. 2015, 11, e1005171. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, J.; Pu, X.M.; Xiong, Y. kshv-mir-k12-1-5p promotes cell growth and metastasis by targeting SOCS6 in Kaposi’s sarcoma cells. Cancer Manag. Res. 2019, 11, 4985–4995. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, T.; Ju, E.; Gao, S.J. Kaposi sarcoma-associated herpesvirus miRNAs suppress CASTOR1-mediated mTORC1 inhibition to promote tumorigenesis. J. Clin. Investig. 2019, 129, 3310–3323. [Google Scholar] [CrossRef] [Green Version]
- Abend, J.R.; Uldrick, T.; Ziegelbauer, J.M. Regulation of tumor necrosis factor-like weak inducer of apoptosis receptor protein (TWEAKR) expression by Kaposi’s sarcoma-associated herpesvirus microRNA prevents TWEAK-induced apoptosis and inflammatory cytokine expression. J. Virol. 2010, 84, 12139–12151. [Google Scholar] [CrossRef] [Green Version]
- Lei, X.; Zhu, Y.; Jones, T.; Bai, Z.; Huang, Y.; Gao, S.J. A Kaposi’s sarcoma-associated herpesvirus microRNA and its variants target the transforming growth factor beta pathway to promote cell survival. J. Virol. 2012, 86, 11698–11711. [Google Scholar] [CrossRef] [Green Version]
- Skalsky, R.L.; Samols, M.A.; Plaisance, K.B.; Boss, I.W.; Riva, A.; Lopez, M.C.; Baker, H.V.; Renne, R. Kaposi’s sarcoma-associated herpesvirus encodes an ortholog of miR-155. J. Virol. 2007, 81, 12836–12845. [Google Scholar] [CrossRef] [Green Version]
- Qin, J.; Li, W.; Gao, S.J.; Lu, C. KSHV microRNAs: Tricks of the Devil. Trends Microbiol. 2017, 25, 648–661. [Google Scholar] [CrossRef]
- Abend, J.R.; Ramalingam, D.; Kieffer-Kwon, P.; Uldrick, T.S.; Yarchoan, R.; Ziegelbauer, J.M. Kaposi’s sarcoma-associated herpesvirus microRNAs target IRAK1 and MYD88, two components of the toll-like receptor/interleukin-1R signaling cascade, to reduce inflammatory-cytokine expression. J. Virol. 2012, 86, 11663–11674. [Google Scholar] [CrossRef] [Green Version]
- Liang, D.; Gao, Y.; Lin, X.; He, Z.; Zhao, Q.; Deng, Q.; Lan, K. A human herpesvirus miRNA attenuates interferon signaling and contributes to maintenance of viral latency by targeting IKKepsilon. Cell Res. 2011, 21, 793–806. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Qin, Z.; Kearney, P.; Plaisance, K.; Parsons, C.H. Pivotal advance: Kaposi’s sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes. J. Leukoc. Biol. 2010, 87, 25–34. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Naqvi, A.R.; Shango, J.; Seal, A.; Shukla, D.; Nares, S. Viral miRNAs Alter Host Cell miRNA Profiles and Modulate Innate Immune Responses. Front. Immunol. 2018, 9, 433. [Google Scholar] [CrossRef] [PubMed]
- Bravo, I.G.; Felez-Sanchez, M. Papillomaviruses: Viral evolution, cancer and evolutionary medicine. Evol. Med. Public Health 2015, 2015, 32–51. [Google Scholar] [CrossRef]
- Bzhalava, D.; Eklund, C.; Dillner, J. International standardization and classification of human papillomavirus types. Virology 2015, 476, 341–344. [Google Scholar] [CrossRef]
- Buck, C.B.; Trus, B.L. The papillomavirus virion: A machine built to hide molecular Achilles’ heels. Adv. Exp. Med. Biol. 2012, 726, 403–422. [Google Scholar]
- Graham, S.V.; Faizo, A.A.A. Control of human papillomavirus gene expression by alternative splicing. Virus Res. 2017, 231, 83–95. [Google Scholar] [CrossRef] [Green Version]
- Zur Hausen, H. Papillomaviruses in the causation of human cancers—A brief historical account. Virology 2009, 384, 260–265. [Google Scholar] [CrossRef] [Green Version]
- Mirghani, H.; Amen, F.; Moreau, F.; Lacau St Guily, J. Do high-risk human papillomaviruses cause oral cavity squamous cell carcinoma? Oral Oncol. 2015, 51, 229–236. [Google Scholar] [CrossRef] [PubMed]
- Chirayil, R.; Kincaid, R.P.; Dahlke, C.; Kuny, C.V.; Dalken, N.; Spohn, M.; Lawson, B.; Grundhoff, A.; Sullivan, C.S. Identification of virus-encoded microRNAs in divergent Papillomaviruses. PLoS Pathog. 2018, 14, e1007156. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Virtanen, E.; Pietila, T.; Nieminen, P.; Qian, K.; Auvinen, E. Low expression levels of putative HPV encoded microRNAs in cervical samples. SpringerPlus 2016, 5, 1856. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Qian, K.; Pietila, T.; Ronty, M.; Michon, F.; Frilander, M.J.; Ritari, J.; Tarkkanen, J.; Paulin, L.; Auvinen, P.; Auvinen, E. Identification and validation of human papillomavirus encoded microRNAs. PLoS ONE 2013, 8, e70202. [Google Scholar] [CrossRef] [PubMed]
- Bernard, H.U.; Apt, D. Transcriptional control and cell type specificity of HPV gene expression. Arch. Dermatol. 1994, 130, 210–215. [Google Scholar] [CrossRef]
- Ishiji, T.; Lace, M.J.; Parkkinen, S.; Anderson, R.D.; Haugen, T.H.; Cripe, T.P.; Xiao, J.H.; Davidson, I.; Chambon, P.; Turek, L.P. Transcriptional enhancer factor (TEF)-1 and its cell-specific co-activator activate human papillomavirus-16 E6 and E7 oncogene transcription in keratinocytes and cervical carcinoma cells. EMBO J. 1992, 11, 2271–2281. [Google Scholar] [CrossRef]
- Martinez-Zapien, D.; Ruiz, F.X.; Poirson, J.; Mitschler, A.; Ramirez, J.; Forster, A.; Cousido-Siah, A.; Masson, M.; Vande Pol, S.; Podjarny, A.; et al. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53. Nature 2016, 529, 541–545. [Google Scholar] [CrossRef] [Green Version]
- Ganguly, N.; Parihar, S.P. Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. J. Biosci. 2009, 34, 113–123. [Google Scholar] [CrossRef]
- Gomez-Gomez, Y.; Organista-Nava, J.; Gariglio, P. Deregulation of the miRNAs expression in cervical cancer: Human papillomavirus implications. Biomed. Res. Int. 2013, 2013, 407052. [Google Scholar] [CrossRef]
- Zheng, Z.M.; Wang, X. Regulation of cellular miRNA expression by human papillomaviruses. Biochim. Biophys. Acta 2011, 1809, 668–677. [Google Scholar] [CrossRef] [Green Version]
- Paiva, I.; da Costa, R.M.G.; Ribeiro, J.; Sousa, H.; Bastos, M.M.; Faustino-Rocha, A.; Lopes, C.; Oliveira, P.A.; Medeiros, R. MicroRNA-21 expression and susceptibility to HPV-induced carcinogenesis—Role of microenvironment in K14-HPV16 mice model. Life Sci. 2015, 128, 8–14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Paiva, I.; da Costa, R.M.G.; Ribeiro, J.; Sousa, H.; Bastos, M.; Faustino-Rocha, A.; Lopes, C.; Oliveira, P.A.; Medeiros, R. A role for microRNA-155 expression in microenvironment associated to HPV-induced carcinogenesis in K14-HPV16 transgenic mice. PLoS ONE 2015, 10, e0116868. [Google Scholar] [CrossRef] [PubMed]
- Krump, N.A.; You, J. Molecular mechanisms of viral oncogenesis in humans. Nat. Rev. Microbiol. 2018, 16, 684–698. [Google Scholar] [CrossRef] [PubMed]
- Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA A Cancer J. Clin. 2011, 61, 69–90. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pollicino, T.; Saitta, C. Occult hepatitis B virus and hepatocellular carcinoma. World J. Gastroenterol. 2014, 20, 5951–5961. [Google Scholar] [CrossRef] [PubMed]
- Yao, L.; Zhou, Y.; Sui, Z.; Zhang, Y.; Liu, Y.; Xie, H.; Gao, H.; Fan, H.; Zhang, Y.; Liu, M.; et al. HBV-encoded miR-2 functions as an oncogene by downregulating TRIM35 but upregulating RAN in liver cancer cells. EBioMedicine 2019, 48, 117–129. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zaoui, K.; Boudhraa, Z.; Khalife, P.; Carmona, E.; Provencher, D.; Mes-Masson, A.M. Ran promotes membrane targeting and stabilization of RhoA to orchestrate ovarian cancer cell invasion. Nat. Commun. 2019, 10, 2666. [Google Scholar] [CrossRef] [Green Version]
- Yang, X.; Li, H.; Sun, H.; Fan, H.; Hu, Y.; Liu, M.; Li, X.; Tang, H. Hepatitis B Virus-Encoded MicroRNA Controls Viral Replication. J. Virol. 2017, 91, e01919-16. [Google Scholar] [CrossRef] [Green Version]
- Choo, Q.L.; Kuo, G.; Weiner, A.J.; Overby, L.R.; Bradley, D.W.; Houghton, M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244, 359–362. [Google Scholar] [CrossRef] [Green Version]
- Russelli, G.; Pizzillo, P.; Iannolo, G.; Barbera, F.; Tuzzolino, F.; Liotta, R.; Traina, M.; Vizzini, G.; Gridelli, B.; Badami, E.; et al. HCV replication in gastrointestinal mucosa: Potential extra-hepatic viral reservoir and possible role in HCV infection recurrence after liver transplantation. PLoS ONE 2017, 12, e0181683. [Google Scholar] [CrossRef] [Green Version]
- Machida, K.; Cheng, K.T.; Sung, V.M.; Shimodaira, S.; Lindsay, K.L.; Levine, A.M.; Lai, M.Y.; Lai, M.M. Hepatitis C virus induces a mutator phenotype: Enhanced mutations of immunoglobulin and protooncogenes. Proc. Natl. Acad. Sci. USA 2004, 101, 4262–4267. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dionisio, N.; Garcia-Mediavilla, M.V.; Sanchez-Campos, S.; Majano, P.L.; Benedicto, I.; Rosado, J.A.; Salido, G.M.; Gonzalez-Gallego, J. Hepatitis C virus NS5A and core proteins induce oxidative stress-mediated calcium signalling alterations in hepatocytes. J. Hepatol. 2009, 50, 872–882. [Google Scholar] [CrossRef] [PubMed]
- Jopling, C.L. Targeting microRNA-122 to Treat Hepatitis C Virus Infection. Viruses 2010, 2, 1382–1393. [Google Scholar] [CrossRef] [PubMed]
- Ottosen, S.; Parsley, T.B.; Yang, L.; Zeh, K.; van Doorn, L.J.; van der Veer, E.; Raney, A.K.; Hodges, M.R.; Patick, A.K. In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Antimicrob. Agents Chemother. 2015, 59, 599–608. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Van der Ree, M.H.; de Vree, J.M.; Stelma, F.; Willemse, S.; van der Valk, M.; Rietdijk, S.; Molenkamp, R.; Schinkel, J.; van Nuenen, A.C.; Beuers, U.; et al. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: A phase 1B, double-blind, randomised controlled trial. Lancet 2017, 389, 709–717. [Google Scholar] [CrossRef]
- Luna, J.M.; Scheel, T.K.; Danino, T.; Shaw, K.S.; Mele, A.; Fak, J.J.; Nishiuchi, E.; Takacs, C.N.; Catanese, M.T.; de Jong, Y.P.; et al. Hepatitis C virus RNA functionally sequesters miR-122. Cell 2015, 160, 1099–1110. [Google Scholar] [CrossRef] [Green Version]
- Hsu, S.H.; Wang, B.; Kota, J.; Yu, J.; Costinean, S.; Kutay, H.; Yu, L.; Bai, S.; La Perle, K.; Chivukula, R.R.; et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J. Clin. Investig. 2012, 122, 2871–2883. [Google Scholar] [CrossRef] [Green Version]
- Tsai, W.C.; Hsu, S.D.; Hsu, C.S.; Lai, T.C.; Chen, S.J.; Shen, R.; Huang, Y.; Chen, H.C.; Lee, C.H.; Tsai, T.F.; et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J. Clin. Investig. 2012, 122, 2884–2897. [Google Scholar] [CrossRef] [Green Version]
- Murakami, Y.; Aly, H.H.; Tajima, A.; Inoue, I.; Shimotohno, K. Regulation of the hepatitis C virus genome replication by miR-199a. J. Hepatol. 2009, 50, 453–460. [Google Scholar] [CrossRef]
- Qureshi, A.; Thakur, N.; Monga, I.; Thakur, A.; Kumar, M. Virmirna: A Comprehensive Resource for Experimentally Validated Viral Mirnas and Their Targets. Database 2014, 2014, bau103. [Google Scholar] [CrossRef]
- Buck, C.B.; Van Doorslaer, K.; Peretti, A.; Geoghegan, E.M.; Tisza, M.J.; An, P.; Katz, J.P.; Pipas, J.M.; McBride, A.A.; Camus, A.C.; et al. The Ancient Evolutionary History of Polyomaviruses. PLoS Pathog. 2016, 12, e1005574. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- DeCaprio, J.A. Merkel cell polyomavirus and Merkel cell carcinoma. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 2017, 372, 20160276. [Google Scholar] [CrossRef] [PubMed]
- Clarke, C.A.; Robbins, H.A.; Tatalovich, Z.; Lynch, C.F.; Pawlish, K.S.; Finch, J.L.; Hernandez, B.Y.; Fraumeni, J.F., Jr.; Madeleine, M.M.; Engels, E.A. Risk of merkel cell carcinoma after solid organ transplantation. J. Natl. Cancer Inst. 2015, 107, dju382. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lanoy, E.; Engels, E.A. Skin cancers associated with autoimmune conditions among elderly adults. Br. J. Cancer 2010, 103, 112–114. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shuda, M.; Feng, H.; Kwun, H.J.; Rosen, S.T.; Gjoerup, O.; Moore, P.S.; Chang, Y. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc. Natl. Acad. Sci. USA 2008, 105, 16272–16277. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Feng, H.; Shuda, M.; Chang, Y.; Moore, P.S. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008, 319, 1096–1100. [Google Scholar] [CrossRef] [Green Version]
- Seo, G.J.; Chen, C.J.; Sullivan, C.S. Merkel cell polyomavirus encodes a microRNA with the ability to autoregulate viral gene expression. Virology 2009, 383, 183–187. [Google Scholar] [CrossRef] [Green Version]
- Theiss, J.M.; Gunther, T.; Alawi, M.; Neumann, F.; Tessmer, U.; Fischer, N.; Grundhoff, A. A Comprehensive Analysis of Replicating Merkel Cell Polyomavirus Genomes Delineates the Viral Transcription Program and Suggests a Role for mcv-miR-M1 in Episomal Persistence. PLoS Pathog. 2015, 11, e1004974. [Google Scholar] [CrossRef]
- Akhbari, P.; Tobin, D.; Poterlowicz, K.; Roberts, W.; Boyne, J.R. MCV-miR-M1 Targets the Host-Cell Immune Response Resulting in the Attenuation of Neutrophil Chemotaxis. J. Investig. Dermatol. 2018, 138, 2343–2354. [Google Scholar] [CrossRef] [Green Version]
- Lee, S.; Paulson, K.G.; Murchison, E.P.; Afanasiev, O.K.; Alkan, C.; Leonard, J.H.; Byrd, D.R.; Hannon, G.J.; Nghiem, P. Identification and validation of a novel mature microRNA encoded by the Merkel cell polyomavirus in human Merkel cell carcinomas. J. Clin. Virol. 2011, 52, 272–275. [Google Scholar] [CrossRef] [Green Version]
- Okkenhaug, K.; Bilancio, A.; Farjot, G.; Priddle, H.; Sancho, S.; Peskett, E.; Pearce, W.; Meek, S.E.; Salpekar, A.; Waterfield, M.D.; et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002, 297, 1031–1034. [Google Scholar] [CrossRef] [PubMed]
- Groettrup, M.; Soza, A.; Eggers, M.; Kuehn, L.; Dick, T.P.; Schild, H.; Rammensee, H.G.; Koszinowski, U.H.; Kloetzel, P.M. A role for the proteasome regulator PA28alpha in antigen presentation. Nature 1996, 381, 166–168. [Google Scholar] [CrossRef] [PubMed]
- Murakami, Y.; Chen, L.F.; Sanechika, N.; Kohzaki, H.; Ito, Y. Transcription factor Runx1 recruits the polyomavirus replication origin to replication factories. J. Cell. Biochem. 2007, 100, 1313–1323. [Google Scholar] [CrossRef] [PubMed]
- Tornesello, M.L.; Annunziata, C.; Tornesello, A.L.; Buonaguro, L.; Buonaguro, F.M. Human Oncoviruses and p53 Tumor Suppressor Pathway Deregulation at the Origin of Human Cancers. Cancers 2018, 10, 213. [Google Scholar] [CrossRef] [PubMed] [Green Version]
VIRUS | miRNA | Targets | Effects of miRNAs |
---|---|---|---|
EBV | ebv-BHRF1-2 | IL-12, CATHEPSIN B, AEP, GILT | Immune evasion |
ebv-BHRF1-3 | BHRF1-3, TAP | ||
ebv-BART1-5p | IL12, CATHEPSIN B, AEP, GILT | ||
ebv-BART2-5p | MICB, IL-12, CATHEPSIN B, AEP, GILT | ||
ebv-BART3-3p | IPO7 | ||
ebv-BART5-5p | LMP1 | ||
ebv-BART6-3p | RIG-1 | ||
ebv-BART15 | NLRP3 | ||
ebv-BART16 | CREB-BP | ||
ebv-BART17-5p | TAP | ||
ebv-BART22 | LMP2A | ||
ebv-BHRF1-1 | P53 | Anti-apoptosis | |
ebv-BHRF1-2 | PRDM1/Blimp1 | ||
ebv-BHRF1-3 | PTEN | ||
ebv-BART1-3p | CASP3 | ||
ebv-BART4-5p | Bid | ||
ebv-BART5-5p | PUMA | ||
ebv-BART6-5p | OCT1 | ||
ebv-BART8 | STAT1 | ||
ebv-BART13-3p | CAPRIN2 | ||
ebv-BART16 | CREB-BP, TOMM22, CASP3, SH2B3 | ||
ebv-BART22 | MAP3K5, CASP3, PAK2, TP53INP1 | ||
ebv-BART22 | NDRG1 | Promote metastasis | |
ebv-BHRF1-1 | RNF4 | Promote viral production | |
ebv-BHRF1-2 | BHRF1 | Maintain latency | |
ebv-BART2-5p | BALF5 | ||
ebv-BART6-5p | DICER | ||
ebv-BART18-5p | MAP3K2 | ||
ebv-BART20-5p | BZLF1, BRLF1 | ||
ebv-BART1-5p | LMP1 | Promote cancer development | |
ebv-BART16 | LMP1 | ||
ebv-BART17-5p | LMP1 | ||
ebv-BART1-5p | PTEN | Promote tumor metastasis | |
ebv-BART7-3p | PTEN | ||
ebv-BART9 | E-Cadherin | ||
ebv-BART10-3p | BTRC | ||
ebv-BART6-3p | PTEN | Promote proliferation | |
ebv-BART11 | FOXP1 | ||
KSHV | kshv-miR-K12-1 | Casp3 | Apoptosis |
kshv-miR-K12-3 | Casp3 | ||
kshv-miR-K12-4 | Casp4 | ||
kshv-miR-K12-5 | Tmskα1 | ||
kshv-miR-K12-10a | TWEAK | ||
kshv-miR-K12-12 | CASP3, CASP7 | ||
kshv-miR-K12-1 | NF-κB signaling/IκBα | KSHV latency | |
kshv-miR-K12-3 | nuclear factor I/B, GRK2 | ||
kshv-miR-K12-4 | Rbl2 | ||
kshv-miR-K12-7 | RTA (KSHV ORF50) | ||
kshv-miR-K12-9 | RTA (KSHV ORF50), BCLAF1 | ||
kshv-miR-K12-10a | BCLAF1 | ||
kshv-miR-K12-11 | MYB, IKKε | ||
kshv-miR-K12-1 | THBS1 | Cell adhesion, migration, and angiogenesis | |
kshv-miR-K12-3 | THBS1 | ||
kshv-miR-K12-6 | THBS1, Bcr, SH3BGR | ||
kshv-miR-K12-11 | THBS1 | ||
kshv-miR-K12-1 | CASTOR1, STAT3,p21 | Promote tumorigenesis, Cell survival | |
kshv-miR-K12-4 | CASTOR1 | ||
kshv-miR-K12-10a | TGFBR2 | ||
kshv-miR-K12-10b | TGFBR2 | ||
kshv-miR-K12-11 | SMAD5 | ||
kshv-miR-K12-1 | MICB | Immune evasion | |
kshv-miR-K12-3 | C/EBPβ p20 (LIP) | ||
kshv-miR-K12-5 | MYD88 | ||
kshv-miR-K12-7 | C/EBPβ p20 (LIP), MICB | ||
kshv-miR-K12-9 | IRAK1 | ||
kshv-miR-K12-11 | C/EBPβ | ||
kshv-miR-K12-1 | MAF | Differentiation of infected cells | |
kshv-miR-K12-6 | MAF | ||
kshv-miR-K12-11 | MAF/BACH-1 | ||
HPV | HPV16-miR-H1 | BCL11A, CHD7, ITGAM, RAG1, TCEA1 | Immune evasion |
HPV16-miR-H2 | SP3, XRCC4, JAK2, PKNOX1, FOXP1 | ||
HBV | HBV-mir-2 | TRIM35 | Promote tumorigenesis |
HBV-mir-3 | HBsAg, HBeAg, HBc | Self-replication | |
MCPyV | MCV-miR-M1-5p | SP100 | Immune evasion |
MCV-miR-M1 | RUNX1 | Viral proliferation |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gallo, A.; Miceli, V.; Bulati, M.; Iannolo, G.; Contino, F.; Conaldi, P.G. Viral miRNAs as Active Players and Participants in Tumorigenesis. Cancers 2020, 12, 358. https://doi.org/10.3390/cancers12020358
Gallo A, Miceli V, Bulati M, Iannolo G, Contino F, Conaldi PG. Viral miRNAs as Active Players and Participants in Tumorigenesis. Cancers. 2020; 12(2):358. https://doi.org/10.3390/cancers12020358
Chicago/Turabian StyleGallo, Alessia, Vitale Miceli, Matteo Bulati, Gioacchin Iannolo, Flavia Contino, and Pier Giulio Conaldi. 2020. "Viral miRNAs as Active Players and Participants in Tumorigenesis" Cancers 12, no. 2: 358. https://doi.org/10.3390/cancers12020358